Barry Canton
CIK: 0001882756
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Ginkgo Bioworks Holdings, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Oct 19, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Sale(S)Indirect22.4K shares at avg. $10.14$227K - Oct 19, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Sale(S)Direct18.8K shares at avg. $10.14$191K - Oct 16, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Exercise(M)Direct26.8K shares- - Oct 16, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Exercise(M)Indirect10.6K shares- - Oct 16, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Exercise(M)Indirect29.3K shares- - Oct 16, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Exercise(M)Direct9.8K shares- - Jul 28, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Award(A)IndirectRestricted Stock Units
127.4K shares- - Jul 28, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Award(A)DirectRestricted Stock Units
35.7K shares- - Jul 28, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Award(A)DirectRestricted Stock Units
117.1K shares- - Jul 28, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Award(A)IndirectRestricted Stock Units
39K shares- - Apr 10, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Sale(S)Indirect124.7K shares at avg. $6.43$802K - Apr 9, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Exercise(M)Indirect251.8K shares- - Apr 9, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Sale(S)Direct13.1K shares at avg. $6.40$84K - Apr 8, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Sale(S)Direct13.2K shares at avg. $6.93$91K - Apr 8, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Exercise(M)Direct27.7K shares- - Apr 7, 2026DNA
Ginkgo Bioworks Holdings, Inc.
Exercise(M)Direct27.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 19, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Sale(S) | 22,369 | $10.14 | $226,889 | Indirect |
| Oct 19, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Sale(S) | 18,803 | $10.14 | $190,719 | Direct |
| Oct 16, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Exercise(M) | 26,802 | - | $0 | Direct |
| Oct 16, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Exercise(M) | 10,619 | - | $0 | Indirect |
| Oct 16, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Exercise(M) | 29,279 | - | $0 | Indirect |
| Oct 16, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Exercise(M) | 9,762 | - | $0 | Direct |
| Jul 28, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Award(A) Restricted Stock Units | 127,423 | - | - | Indirect |
| Jul 28, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Award(A) Restricted Stock Units | 35,736 | - | - | Direct |
| Jul 28, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Award(A) Restricted Stock Units | 117,135 | - | - | Direct |
| Jul 28, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Award(A) Restricted Stock Units | 39,038 | - | - | Indirect |
| Apr 10, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Sale(S) | 124,727 | $6.43 | $802,494 | Indirect |
| Apr 9, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Exercise(M) | 251,786 | - | $0 | Indirect |
| Apr 9, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Sale(S) | 13,116 | $6.40 | $83,903 | Direct |
| Apr 8, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Sale(S) | 13,155 | $6.93 | $91,164 | Direct |
| Apr 8, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Exercise(M) | 27,738 | - | $0 | Direct |
| Apr 7, 2026 | DNA Ginkgo Bioworks Holdings, Inc. | Exercise(M) | 27,738 | - | $0 | Direct |
1-16 of 16 transactions
About Canton Barry
Canton Barry (SEC CIK 0001882756) files insider reports with the SEC as 10% Owner of Ginkgo Bioworks Holdings, Inc. (DNA).
Signal8 holds 4 ownership filings by Canton Barry, all Form 4s, filed between Apr 10, 2026 and Oct 21, 2026. Those filings report 16 transactions, from Apr 7, 2026 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Canton Barry's filings is in BOSTON, MA.
Recent filings by Canton Barry
- Oct 19, 2026: Open-market sales of DNA shares (2 lines, Form 4, code S).
- Oct 16, 2026: Option exercises of DNA shares (4 lines, Form 4, code M).
- Jul 28, 2026: Grants or awards of DNA derivative securities (4 lines, Form 4, code A).
- Apr 10, 2026: Open-market sale of DNA shares (Form 4, code S).
- Apr 9, 2026: Option exercise of DNA shares (Form 4, code M).
Other insiders filing for Ginkgo Bioworks Holdings, Inc. (DNA)
- Coen Steven P.
- Shetty Reshma P.
- Kelly Jason R
- HENRY CHRISTIAN O, Director
- Fubini Ross, Director
- Kosuri Sri, Director